O'Shaughnessy Ventures Support: Revolutionizing Clinical Trials with Home Testing Solutions
O'Shaughnessy Ventures LLC (OSV) has recently awarded its prestigious O'Shaughnessy Fellowship to Fengyi Zheng, a talented biomedical researcher and entrepreneur based in Boston, Massachusetts. This fellowship comes as a significant recognition for Zheng's innovative work in the realm of clinical trials, specifically her project named BioMe. The initiative aims to revolutionize the way motor function assessments are performed by utilizing artificial intelligence (AI) to analyze motion tracking from videos recorded at home, thus removing barriers that often limit patient participation in clinical trials.
Historically, clinical trials have relied upon subjective evaluations conducted in clinical settings, which can be heavily influenced by geographical factors and personal biases. With her background in mathematics and statistics from the University of Wisconsin-Madison, Zheng has a firm grasp on the challenges posed by these outdated methods. Her experience at the Broad Institute of MIT and Harvard, where her work on CRISPR technology was highly regarded, has further equipped her with the knowledge and skills necessary to push the boundaries of current practices.
BioMe is set to transform the traditional approach by allowing patients to record their movements in the comfort of their own homes. By employing advanced AI algorithms for motion analysis, the platform can convert everyday videos into precise, study-ready measurements. This innovation is especially critical in today’s healthcare landscape, where underrepresented populations often remain sidelined due to restrictive clinical trial participation criteria.
In her own words, Zheng expressed, "I'm grateful for the O'Shaughnessy Fellowship and excited to be joining this community. Underrepresented and biased data in healthcare are among the most important problems we face. They shape which treatments get built and who they actually work for. I look forward to working on this alongside a rigorous, diverse community that genuinely cares about the world."
Jim O'Shaughnessy, the firm's founder and CEO, hailed Zheng’s initiative, stating, "The quality of clinical trial data influences which treatments reach patients and who those patients are. Fengyi is tackling that problem from the ground up. We're thrilled to support her in taking BioMe to the next level."
The O'Shaughnessy Fellowships were launched in 2023 with the intent to discover and empower innovative creatives and researchers. Each fellow is granted funding up to $100,000 and gains access to a collaborative network of founders, investors, and domain experts, which can vastly enhance their projects. In 2026, OSV intends to allocate up to 20 fellowships, furthering its commitment to fostering innovation.
Fengyi Zheng’s BioMe project not only showcases the potential to enhance clinical trial data integrity but also ensures that more diverse patient populations can contribute to and benefit from medical advancements. In a world where healthcare disparities often dictate treatment outcomes, BioMe serves as a beacon of hope, sparking a necessary dialogue around inclusivity in clinical research. The potential impact of such innovations underscores the critical role that supportive initiatives like the O'Shaughnessy Fellowship play in nurturing groundbreaking ideas that could reshape our understanding of healthcare.
As applications for the next round of fellowships remain open through April 30, 2026, aspiring innovators are encouraged to apply via the OSV website. The collective efforts of creative minds like Fengyi Zheng are paving the way for a more equitable and scientifically advanced future in healthcare, where AI and technology stand at the forefront of medical exploration and patient care enhancement.
Historically, clinical trials have relied upon subjective evaluations conducted in clinical settings, which can be heavily influenced by geographical factors and personal biases. With her background in mathematics and statistics from the University of Wisconsin-Madison, Zheng has a firm grasp on the challenges posed by these outdated methods. Her experience at the Broad Institute of MIT and Harvard, where her work on CRISPR technology was highly regarded, has further equipped her with the knowledge and skills necessary to push the boundaries of current practices.
BioMe is set to transform the traditional approach by allowing patients to record their movements in the comfort of their own homes. By employing advanced AI algorithms for motion analysis, the platform can convert everyday videos into precise, study-ready measurements. This innovation is especially critical in today’s healthcare landscape, where underrepresented populations often remain sidelined due to restrictive clinical trial participation criteria.
In her own words, Zheng expressed, "I'm grateful for the O'Shaughnessy Fellowship and excited to be joining this community. Underrepresented and biased data in healthcare are among the most important problems we face. They shape which treatments get built and who they actually work for. I look forward to working on this alongside a rigorous, diverse community that genuinely cares about the world."
Jim O'Shaughnessy, the firm's founder and CEO, hailed Zheng’s initiative, stating, "The quality of clinical trial data influences which treatments reach patients and who those patients are. Fengyi is tackling that problem from the ground up. We're thrilled to support her in taking BioMe to the next level."
The O'Shaughnessy Fellowships were launched in 2023 with the intent to discover and empower innovative creatives and researchers. Each fellow is granted funding up to $100,000 and gains access to a collaborative network of founders, investors, and domain experts, which can vastly enhance their projects. In 2026, OSV intends to allocate up to 20 fellowships, furthering its commitment to fostering innovation.
Fengyi Zheng’s BioMe project not only showcases the potential to enhance clinical trial data integrity but also ensures that more diverse patient populations can contribute to and benefit from medical advancements. In a world where healthcare disparities often dictate treatment outcomes, BioMe serves as a beacon of hope, sparking a necessary dialogue around inclusivity in clinical research. The potential impact of such innovations underscores the critical role that supportive initiatives like the O'Shaughnessy Fellowship play in nurturing groundbreaking ideas that could reshape our understanding of healthcare.
As applications for the next round of fellowships remain open through April 30, 2026, aspiring innovators are encouraged to apply via the OSV website. The collective efforts of creative minds like Fengyi Zheng are paving the way for a more equitable and scientifically advanced future in healthcare, where AI and technology stand at the forefront of medical exploration and patient care enhancement.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.